United Therapeutics CORP Form 4 insider transactions

CFO James Edgemond exercised 21,000 options at $146.03 and sold all resulting shares at ~$464–$476 under a 10b5-1 plan, maintaining 8,118 direct shares and 21,517 options outstanding.

CEO Martine Rothblatt exercised options at $120.26 and sold 8,000 shares on Nov. 14 and Nov. 17, 2025 under a pre-set Rule 10b5-1 plan.

United Therapeutics Chairperson & CEO Martine Rothblatt exercised stock options and sold 8,000 common shares under a pre-arranged 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold 11,000 shares of common stock on November 13, 2025, under a pre-arranged 10b5-1 plan.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock under a pre-arranged 10b5-1 trading plan on November 10 and 11, 2025.

United Therapeutics' President and COO, Michael Benkowitz, executed pre-planned stock option exercises and subsequent sales of common stock totaling 22,500 shares.

United Therapeutics CFO James Edgemond exercised stock options and sold 21,000 shares of common stock for over $446 per share under a pre-arranged trading plan.

United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options and sold common stock totaling 8,000 shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock totaling 8,000 shares over two days in November 2025, pursuant to a pre-arranged 10b5-1 trading plan.

United Therapeutics CFO James Edgemond exercised stock options and subsequently sold 21,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock totaling 8,000 shares across two dates in late October and early November 2025, pursuant to a pre-arranged 10b5-1 trading plan.

United Therapeutics' President and COO, Michael Benkowitz, exercised stock options and subsequently sold common stock shares totaling over $10 million, all under a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Christopher Causey reported gifting 450 shares of common stock, reducing his direct beneficial ownership to 4,190 shares.

United Therapeutics CEO Martine Rothblatt discloses planned future stock option exercises and sales under a 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold 11,000 shares under a pre-arranged 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised stock options and sold common stock on October 27 and 28, 2025, under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp's President and COO, Michael Benkowitz, executed a pre-planned sale of common stock following the exercise of stock options.

United Therapeutics Director Christopher Causey filed a Form 4 to correct previously overstated beneficial ownership following an unauthorized share transfer.

United Therapeutics CEO Martine Rothblatt executed stock options and sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed planned stock option exercises and subsequent sales of common stock under a Rule 10b5-1 trading plan.

United Therapeutics' President and COO, Michael Benkowitz, exercised stock options and subsequently sold 22,500 shares of common stock for a significant profit, pursuant to a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised and sold common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and sold 11,000 shares under a pre-arranged 10b5-1 plan.

United Therapeutics CEO Martine Rothblatt exercised and sold common stock options totaling 8,000 shares over two days as part of a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp's Chairperson and CEO, Martine A. Rothblatt, exercised and sold common stock options totaling 8,000 shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics' President and COO, Michael Benkowitz, executed a pre-arranged 10b5-1 plan, exercising stock options and selling 22,500 shares for approximately $9.9 million.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp's Chairperson & CEO, Martine A. Rothblatt, executed pre-arranged sales of common stock totaling 8,000 shares from option exercises on October 7 and 8, 2025, under a 10b5-1 trading plan.

United Therapeutics' President and COO, Michael Benkowitz, executed pre-planned sales of common stock totaling 22,500 shares on October 6, 2025, following option exercises.

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed and sold common stock under a pre-arranged 10b5-1 trading plan.